PT Pyridam Farma Tbk (ISX:PYFA) Current Deferred Revenue: Rp0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:PYFA PT Pyridam Farma Tbk ISX:PYFA
61 GF Score
Price Rp260.00
GF Value Rp229.79
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is PT Pyridam Farma Tbk Current Deferred Revenue?

PT Pyridam Farma Tbk ISX:PYFA -5.11% 61 Current Deferred Revenue is Rp0 Mil as of Jun. 2026. GuruFocus rates ISX:PYFA with a GF Score™ of 61/100 and a GF Value™ of Rp229.79 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

PT Pyridam Farma Tbk's current deferred revenue for the quarter that ended in Jun. 2026 was Rp0 Mil.

PT Pyridam Farma Tbk Current Deferred Revenue Related Terms

PT Pyridam Farma Tbk Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for PT Pyridam Farma Tbk's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Pyridam Farma Tbk Current Deferred Revenue Chart

PT Pyridam Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PT Pyridam Farma Tbk Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ISX:PYFA
61GF Score
PT Pyridam Farma Tbk ISX:PYFA
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of Rp0 Mil mean?
PT Pyridam Farma Tbk (ISX:PYFA) has a Current Deferred Revenue of Rp0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on PT Pyridam Farma Tbk and its competitors.
Is PT Pyridam Farma Tbk's Current Deferred Revenue too high?
PT Pyridam Farma Tbk's current Current Deferred Revenue is Rp0 Mil. Overall, PT Pyridam Farma Tbk has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's Current Deferred Revenue compare to ZTS and UTHR?
PT Pyridam Farma Tbk's Current Deferred Revenue of Rp0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on PT Pyridam Farma Tbk and its competitors. PT Pyridam Farma Tbk's current Current Deferred Revenue is Rp0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Modestly Overvalued. The stock's GF Value™ is Rp229.79, compared to a current price of Rp260.00 — trading 13.1% above its estimated fair value. The current Current Deferred Revenue is Rp0 Mil. PT Pyridam Farma Tbk's overall GF Score™ is 61/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current Current Deferred Revenue is Rp0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be overvalued. The current stock price of Rp260.00 is trading 13.1% above its estimated GF Value™ of Rp229.79. GuruFocus considers PT Pyridam Farma Tbk to be Modestly Overvalued.

Key valuation signals for ISX:PYFA:

  • Current Deferred Revenue: Rp0 Mil
  • GF Value™: Rp229.79 vs. price of Rp260.00 (13.1% above fair value)
  • GF Score™: 61/100 with 8 warning signs

No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Pyridam Farma Tbk Business Description

Address Jl. Jenderal Sudirman Kav. 21, Sinar Mas Land Plaza Sudirman 12th Floor, RT 10/RW 01 Kuningan, Karet, Jakarta Selatan, Jakarta, IDN, 12920
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
61GF Score

Get the complete analysis for ISX:PYFA

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp260.00
Price
Rp229.79
GF Value